Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

DF-conjugated hyaluronate eases pain in knee OA

11 Nov 2020

Repeated doses of diclofenac etalhyaluronate (DF-HA) yield improvements in knee osteoarthritis (OA) pain without major safety signals, with the effect occurring as early as week 1, according to the results of a phase II trial.

In the trial, 176 patients (average age, 64.25 years; 73.3 percent female; mean body mass index, 25 kg/m2) were randomized to receive treatment with 30-mg DF-HA (n=87) or placebo (n=89), administered intra-articularly at weeks 0, 4, and 8 and were followed for 24 weeks.

Both groups achieved pain relief over 12 weeks, although DF-HA produced significantly greater changes in the WOMAC pain subscore (mean difference [MD], –7.0 mm, 95 percent confidence interval [CI], 12.7–1.2; p=0.018), 50-foot walk test pain score (MD, –5.0 mm, 95 percent CI, 10.3–0.3; p=0.065), and daily pain score (MD, –0.61, 95 percent CI, 1.06–0.16; p=0.008).

Pain relief in the DF-HA group was observed at week 1 and sustained through week 12 and week 24.

Treatment with DF-HA also led to substantial improvements in the secondary outcomes of WOMAC physical function subscore (MD, –6.7, 95 percent CI, 12.0–1.4; p=0.014), patient global assessment (MD, –7.6, 95 percent CI, 12.7–2.5; p=0.004), and physician global assessment (MD, 5.1, 95 percent CI, 9.4–0.7; p=0.023).

There was no significant difference in the incidence of treatment-emergent adverse events (TEAEs) between the two treatment groups (57.5 percent vs 58.4 percent). None of the patients died, and serious TEAEs occurred in one patient injected with DF-HA and two patients injected with placebo, none of which were treatment-related.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).